Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — VialBase Research

Summary

SELECT was the landmark cardiovascular outcomes trial (CVOT) of semaglutide 2.4 mg in patients with overweight/obesity and established cardiovascular disease but WITHOUT diabetes. The trial demonstrated a significant 20% reduction in major adverse cardiovascular events, establishing that semaglutide’s cardiovascular benefits extend beyond the diabetic population.

Key Findings

• 20% reduction in 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke): HR 0.80 (95% CI 0.72-0.90)
• Enrolled 17,604 patients — one of the largest obesity trials ever conducted
• Mean weight loss of ~9.4% at mean follow-up of ~40 months
• Cardiovascular benefit observed regardless of baseline weight category
• Benefits emerged early and were sustained throughout follow-up
• Supports a new cardiovascular indication for semaglutide

Methodology

Double-blind, placebo-controlled, event-driven CVOT. 17,604 adults aged ≥45 with BMI ≥27, established CVD, and no diabetes randomized 1:1 to semaglutide 2.4 mg or placebo weekly. Median follow-up 39.8 months. Primary endpoint: time to first MACE.

Limitations

• All patients had established cardiovascular disease — primary prevention not studied
• Weight loss in SELECT (~9.4%) was lower than in STEP 1 (~15%) — likely due to older, sicker population
• Cannot determine whether CV benefit is mediated by weight loss or direct GLP-1 effects
• Does not include patients with diabetes (covered by SUSTAIN-6)
• Most participants were male (72%) and White

Relevance to Content

Game-changing trial that moves semaglutide from “weight loss drug” to “cardiovascular medicine.” The 17,604-patient size gives tremendous authority. Essential for any content discussing semaglutide safety or positioning it as a health intervention (not just cosmetic weight loss). This is the trial that supports the “semaglutide saves lives” argument.

See Also

• Parent compound: Semaglutide